<!DOCTYPE html>
<html>
    <head>
        <title>HP | Entrepreneurship | iGem Winter Project</title>
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <link rel="icon" type="image/png" href="../../static/img/favicon.ico">
        <script type="module" src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.esm.js"></script>
        <script nomodule src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.js"></script>
        <link rel="stylesheet" href="../../static/css/basic.css">
        <link rel="stylesheet" href="../../static/css/load.css">
        <link rel="stylesheet" href="../../static/css/pages.css">
        <link rel="stylesheet" href="../../static/css/components.css">
        <style>
            .quote {
                font-size: 20px;  /* zoom font size */
            }
        </style>
    </head>
    <body>
        <!-- scroll progress bar -->
        <div class="scroll-progress"></div>
        
        <!-- Loading cast -->
        <div class="loading-container">
            <div class="loading-spinner-image">
                <img src="../../static/img/loading.svg" alt="Loading...">
            </div>
            <div class="loading-text">Loading...</div>
        </div>

        <div class="top_bar">
            <div class="menu_btn">
                <ion-icon name="menu-outline"></ion-icon>
            </div>
            <div class="logo_wrap">
                <a href="../../index.html"><img id="team_logo" src="../../static/img/logo-apart-text.svg" alt=""></a>
            </div>
            <div class="menu_wrap">
                <div id="project" class="menu_item">
                    <div class="title">Project<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../description.html">Description</a></li>
                        <li><a href="../design.html">Design</a></li>
                        <li><a href="../safety.html">Safety</a></li>
                    </ul>
                </div>
                <div id="wetlab" class="menu_item">
                    <div class="title">Wet Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../wetlab/engineering.html">Engineering</a></li>
                        <li><a href="../wetlab/construction.html">Construction</a></li>
                        <li><a href="../wetlab/protocol.html">Protocol</a></li>
                        <li><a href="../wetlab/parts.html">Parts</a></li>
                    </ul>
                </div>
                <div id="drylab" class="menu_item">
                    <div class="title">Dry Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../drylab/model&software.html">Model & Software</a></li>
                        <li><a href="../drylab/hardware.html">Hardware</a></li>
                    </ul>
                </div>
                <div id="human" class="menu_item">
                    <div class="title">Human Practice<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./overview.html">Overview</a></li>
                        <li><a href="./education.html">Education</a></li>
                        <li><a href="./entrepreneurship.html">Entrepreneurship</a></li>
                        <li><a href="./integrated.html">Integrated Human Practices</a></li>
                        <li><a href="./inclusivity.html">Inclusivity</a></li>
                        <li><a href="./sustain.html">Sustainable Development</a></li>
                        <li><a href="./ethical.html">Ethical Framework</a></li>
                    </ul>
                </div>
                <div id="team" class="menu_item">
                    <div class="title">Team<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="../team/attributions.html">Attributions</a></li>
                        <li><a href="../team/member.html">Member</a></li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Page Title Background -->
        <div class="page-title-bg">
            <div class="bg-image" style="background-image: url('../../static/img/hp-overview/overview.png')"></div>
            <div class="overlay"></div>
            <div class="title-content">
                <h1>Entrepreneurship</h1>
            </div>
        </div>

        <!-- Main content wrapper -->
        <div class="main">
            <!-- Sidebar wrapper -->
            <div class="sidebarBg">
                <div class="sidebar">
                    <div class="sidebar-collapse-btn">
                        <ion-icon name="chevron-back-outline"></ion-icon>
                    </div>
                    
                    <div class="t1">
                        <span>Market Analysis</span>
                        <div class="t2">
                            <a href="#pestel">PESTEL Analysis</a>
                            <a href="#competitive">Competitive Analysis</a>
                            <a href="#swot">SWOT Analysis</a>
                            <a href="#cooperative">Potential partners</a>
                            <a href="#investment">Source of investment</a>
                        </div>
                    </div>
                    <div class="t1">
                        <span>Marketing and Implementation Strategy</span>
                        <div class="t2">
                            <a href="#request-analysis">Analysis of User Requests</a>
                            <a href="#marketing-strategy">Marketing Strategy</a>
                            <a href="#implementation">Implementation Strategy</a>
                        </div>
                    </div>
                    <div class="t1">
                        <span>Project Risk Analysis</span>
                        <div class="t2">
                            <a href="#deterministic">Deterministic Risk</a>
                            <a href="#uncertainty">Uncertainty Risk</a>
                        </div>
                    </div>
                    <div class="t1">
                        <a href="#references">References</a>
                    </div>
                </div>
            </div>

            <!-- sidebar expand button -->
            <div class="sidebar-expand-btn">
                <ion-icon name="chevron-forward-outline"></ion-icon>
            </div>

            <!-- Content area -->
            <div class="content">

                <section id="introduction">
                    <blockquote class="quote">
                        "Make technology accessible, make the business flourish"
                        <div class="quote-source">
                            - ClearCats Â® redefines the future of eye care.                        </div>
                    </blockquote>

                    <p>In the entrepreneurship sector, we have laid a solid foundation for the monetization of the project through systematic market analysis and accurate strategic planning. We used <strong>PESTEL analysis</strong>, <strong>Porter Five Force model</strong>, <strong>SWOT analysis</strong>, and other tools to comprehensively evaluate the market environment, competition landscape, and potential partners to ensure that the decision is scientific and forward-looking. In terms of financing, we have formulated a multi-stage investment strategy covering <strong>seed rounds to IPO</strong>, accurately matching the capital needs of different stages of development to ensure that the project has sufficient capital support from prototype development to global market expansion.</p>

                    <p>We focus on the two core groups of cataract patients and contact lens users, clarify value propositions, innovate promotion methods, and combine <strong>B2B and B2C</strong> channels, to expand product coverage. We enhance brand influence through authoritative endorsement, digital marketing, and public welfare linkage and create a reliable product image. We have planned a phased promotion path from pilot to globalization, built a partner ecosystem covering research and development, production, and public welfare, and improved the user support system to ensure continuous optimization and user satisfaction after launching the product.</p>

                    <p>In short, our work in the entrepreneurship section not only focuses on <strong>technological innovation</strong>, but also pays more attention to the dual realization of <strong>commercial feasibility</strong> and <strong>social value</strong>, striving to make every lens a step towards changing the world.</p>
                </section>


                <!-- <section id="market-analysis"> -->
                <h1>Market Analysis</h1>
                <section id="pestel">
                    <h2>PESTEL Analysis</h2>
                        
                    <div class="note-box">
                        <p><strong>Note:</strong> The following types of analysis are not from professional sources. When the actual project is implemented, it is necessary to seek help and support from the School of Economics. In the following attachment, I listed a series of experts, professors, and researchers that can be considered for advice, or if needed, we could seek analysis from graduate and doctoral students in the School of Economics. Multiple-party contact increases the possibility of finding help (Attachment 1).</p>
                    </div>

                    <div class="table-container">
                        <table>
                            <caption>PESTEL Analysis of ClearCats Project</caption>
                            <thead>
                                <tr>
                                    <th>Dimension</th>
                                    <th>Analyze content</th>
                                    <th>Opportunities and challenges</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Political</strong></td>
                                    <td><strong>Policy support:</strong> China's "14th Five-Year Plan" focuses on supporting biomedical innovation. Hangzhou's "Eagle Plan" may provide entrepreneurial funding.<br><br>
                                    <strong>Regulatory barriers:</strong> the approval cycle of the third category of medical apparatus is long (3-5 years), and it needs to be strictly reviewed by the National Medical Products Administration (NMPA).</td>
                                    <td>
                                        <strong>Opportunity:</strong> Accelerate approval through green channel.<br>
                                        <strong>Challenge:</strong> High compliance costs.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Economic</strong></td>
                                    <td><strong>Market size:</strong> The global ophthalmic drug market is expected to reach 46 billion dollars by 2025, and China's annual growth rate will exceed 15%<sup><a href="#ref8"></a>[8]</a> <a href="#ref9">[9]</a></sup>.<br><br>
                                    <strong>Cost pressure:</strong> Patients in developing countries have limited payment ability and need to reduce costs through large-scale production.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Potential for medical insurance coverage.<br>
                                        <strong>Challenge:</strong> High price sensitivity.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Social</strong></td>
                                    <td><strong>Aging trend:</strong> The proportion of the population over 60 years old in China has reached 20%, and the incidence of cataracts increases significantly with age.<br><br>
                                    <strong>Increased health awareness:</strong> Consumers' preference for non-invasive treatments has increased.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Precise positioning of the elderly market.<br>
                                        <strong>Challenge:</strong> Insufficient primary medical education.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Technological</strong></td>
                                    <td><strong>Breakthrough in synthetic biology:</strong> CRISPR engineering bacteria, targeted delivery technology, and other synthetic biology methods have matured.<br><br>
                                    <strong>Competing product threat:</strong> Novartis, Alcon and other pharmaceutical companies layout nano eye drops, but lack of long-term sustained-release solutions.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Technological differentiation.<br>
                                        <strong>Challenge:</strong> Patent barriers need to be broken through.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Environmental</strong></td>
                                    <td><strong>Sustainable production:</strong> Hydrogel materials must meet biodegradable standards to avoid microplastic pollution.<br><br>
                                    <strong>Carbon footprint management:</strong> Hangzhou Pharmaceutical Port Town requires companies to pass green factory certification.</td>
                                    <td>
                                        <strong>Opportunity:</strong> Environmental protection brand premium.<br>
                                        <strong>Challenge:</strong> High cost of degradable materials.
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>Legal</strong></td>
                                    <td><strong>Biosafety Law:</strong> Engineering bacteria must meet the dual physical packaging requirements of the Biosafety Law.<br><br>
                                    <strong>Intellectual property rights:</strong> Need to lay out core patents (such as RNF114 targeted modification technology).</td>
                                    <td>
                                        <strong>Opportunity:</strong> Policy compliance enhances trust;<br>
                                        <strong>Challenge:</strong> Complex international patent layout.
                                        </td>
                                    </tr>
                                </tbody>
                        </table>
                        <div class="table-note">
                            Data sources: Market research and industry reports [8][9]
                        </div>
                    </div>
                </section>

                <section id="competitive">
                    <h2>Competitive Analysis Based on Porter's Five Forces Model</h2>

                    <div class="five-forces-diagram">
                        <div class="center-circle">
                            <span>Five Forces<br>Model</span>
                        </div>
                        <div class="force-circle top">
                            <span>Threat of<br>New<br>Entrants</span>
                        </div>
                        <div class="force-circle right">
                            <span>Threat of<br>Substitutes</span>
                        </div>
                        <div class="force-circle bottom-right">
                            <span>Bargaining<br>Power of<br>Buyers</span>
                        </div>
                        <div class="force-circle bottom-left">
                            <span>Bargaining<br>Power of<br>Suppliers</span>
                        </div>
                        <div class="force-circle left">
                            <span>Rivalry<br>Among<br>Existing<br>Competitors</span>
                        </div>
                    </div>

                    <style>
                        .five-forces-diagram {
                            position: relative;
                            width: 600px;
                            height: 600px;
                            margin: 50px auto;
                        }

                        .force-circle, .center-circle {
                            position: absolute;
                            background: #f0f0f0;
                            border-radius: 50%;
                            display: flex;
                            align-items: center;
                            justify-content: center;
                            text-align: center;
                            font-size: 16px;
                            transition: all 0.3s ease;
                        }

                        .center-circle {
                            width: 120px;
                            height: 120px;
                            background: #666;
                            color: white;
                            left: 50%;
                            top: 50%;
                            transform: translate(-50%, -50%);
                            z-index: 2;
                        }

                        .force-circle {
                            width: 150px;
                            height: 150px;
                        }

                        .top {
                            left: 50%;
                            top: 50px;
                            transform: translateX(-50%);
                            background: #ffdd99;
                        }

                        .right {
                            right: 50px;
                            top: 45%;
                            transform: translateY(-50%);
                            background: #ddb0dd;
                        }

                        .bottom-right {
                            right: 120px;
                            bottom: 80px;
                            background: #fff1a2;
                        }

                        .bottom-left {
                            left: 120px;
                            bottom: 80px;
                            background: #87ceeb;
                        }

                        .left {
                            left: 50px;
                            top: 45%;
                            transform: translateY(-50%);
                            background: #d4baef;
                        }

                        .force-circle:hover {
                            transform: scale(1.1);
                            background: #ffdada;
                        }

                        .top:hover {
                            transform: translateX(-50%) scale(1.1);
                            background: #ffdada;
                        }

                        .right:hover, .left:hover {
                            transform: translateY(-50%) scale(1.1);
                            background: #daf6ff;
                        }

                        .five-forces-diagram::before {
                            content: '';
                            position: absolute;
                            width: 60%;
                            height: 60%;
                            left: 50%;
                            top: 50%;
                            transform: translate(-50%, -50%);
                            border: 2px solid #ccc;
                            border-radius: 50%;
                            z-index: -1;
                        }

                        @media (max-width: 900px) {
                            .force-circle, .center-circle {
                                width: 90px;
                                height: 90px;
                                font-size: 11px;
                            }
                            .five-forces-diagram {
                                width: 400px;
                                height: 400px;
                            }
                            .bottom-left {
                                left: 100px;
                                bottom: 45px;
                            }
                            .bottom-right {
                                right: 100px;
                                bottom: 45px;
                            }
                            
                        }
                    </style>

                    <div class="table-container" style="width: 95%; margin: 20px auto;">
                        <table style="width: 100%;">
                            <caption>Porter's Five Forces Analysis of ClearCats Project</caption>
                            <thead>
                                <tr>
                                    <th style="width: 15%;">Five forces dimension</th>
                                    <th style="width: 35%;">Analyze content</th>
                                    <th style="width: 15%;">Threat level to the project</th>
                                    <th style="width: 35%;">Response strategies</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Rivalry among existing competitors</td>
                                    <td>
                                        <strong>Main competitors:</strong> traditional cataract surgery (Aier Eye Hospital, Novartis), nano eye drops (such as Novartis' Xiidra).<br><br>
                                        <strong>Competition focus:</strong> treatment cost, convenience, safety.<br><br>
                                        <strong>Status:</strong> Surgery is the gold standard, but the quota is uneven; the effect of eye drops is limited.
                                    </td>
                                    <td>Medium to high</td>
                                    <td>Differentiated competition: Focus on "non-surgical + long-acting sustained-release", avoid direct competition with the surgical market, and focus on developing countries and contact lens users.</td>
                                </tr>
                                <tr>
                                    <td>Bargaining power of suppliers</td>
                                    <td>
                                        <strong>Key suppliers:</strong> bio-hydrogel materials (PVA/hyaluronic acid), engineered bacterial chassis (Shuffle Escherichia coli), fluorescent protein (Crimson).<br><br>
                                        <strong>Supplier concentration:</strong> Material suppliers are scattered, and engineering technology relies on cooperation with universities.
                                    </td>
                                    <td>Low</td>
                                    <td>Vertical integration: Collaborate with the School of Materials Science and Technology at Zhejiang University to develop self-developed hydrogels and reduce external dependence.</td>
                                </tr>
                                <tr>
                                    <td>Bargaining power of buyers</td>
                                    <td>
                                        <strong>Hospitals/clinics:</strong> price-sensitive to innovative medical apparatus, but demand is rigid (developing countries urgently need alternatives).<br><br>
                                        <strong>Consumers:</strong> Individual users are price-sensitive, but can be bound to medical insurance or public welfare subsidies.
                                    </td>
                                    <td>Medium</td>
                                    <td>Tiered pricing: Hospitals purchase at high prices (covering R & D costs), while developing countries provide a public welfare version (simplifying functions).</td>
                                </tr>
                                <tr>
                                    <td>Threat of substitutes</td>
                                    <td>
                                        <strong>Direct substitution:</strong> gene therapy (such as CRISPR editing of lens cells), stem cell regeneration technology (still in the laboratory stage).<br><br>
                                        <strong>Indirect substitution:</strong> upgraded version of traditional eye drops (such as nanoliposome delivery).
                                    </td>
                                    <td>Low to medium</td>
                                    <td>Technical Competitive Edge: Accelerate patent layout (6 core patents have been planned), establish a dual barrier of "slow-release technology + engineering bacteria".</td>
                                </tr>
                                <tr>
                                    <td>Threat of new entrants</td>
                                    <td>
                                        <strong>Entry barriers:</strong> three types of medical apparatus approval (3-5 years), synthetic biology technology threshold, large-scale production costs.<br><br>
                                        <strong>Potential entrants:</strong> Multinational pharmaceutical companies (such as Johnson & Johnson and Bausch & Lomb) may enter through acquisitions or generics.
                                    </td>
                                    <td>Medium</td>
                                    <td>First-mover advantage: Seize the market through rapid clinical trials (in conjunction with Hangzhou Food and Drug Administration's green channel) and bind research and development resources from universities.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </section>

                <section id="swot">
                    <h2>SWOT Analysis</h2>
                    
                    <div class="swot-container">
                        <div class="swot-grid">
                            <div class="swot-item strengths">
                                <div class="swot-card">
                                    <div class="swot-front">
                                        <h3 class="swot-title">Strengths</h3>
                                        <div class="swot-letter">S</div>
                                    </div>
                                    <div class="swot-back">
                                        <ul>
                                            <li>World's first "engineered bacteria + contact lenses" treatment platform</li>
                                            <li>Multiple indications for expansion (dry eye, glaucoma)</li>
                                            <li>Strong support from Zhejiang University's industry-university-research resources</li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            <div class="swot-item weaknesses">
                                <div class="swot-card">
                                    <div class="swot-front">
                                        <h3 class="swot-title right-title">Weaknesses</h3>
                                        <div class="swot-letter left-letter">W</div>
                                    </div>
                                    <div class="swot-back">
                                        <ul>
                                            <li>Engineering bacteria stability needs optimization for single pair usage duration</li>
                                            <li>Treatment effectiveness requires further experimental verification</li>
                                            <li>Complex mass production process</li>
                                            <li>Insufficient international patent layout</li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            <div class="swot-item opportunities">
                                <div class="swot-card">
                                    <div class="swot-front">
                                        <h3 class="swot-title">Opportunities</h3>
                                        <div class="swot-letter">O</div>
                                    </div>
                                    <div class="swot-back">
                                        <ul>
                                            <li>Intensifying aging population and increasing patient numbers</li>
                                            <li>Urgent non-surgical needs in developing countries</li>
                                            <li>SDGs driving inclusive healthcare investment</li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            <div class="swot-item threats">
                                <div class="swot-card">
                                    <div class="swot-front">
                                        <h3 class="swot-title right-title">Threats</h3>
                                        <div class="swot-letter left-letter">T</div>
                                    </div>
                                    <div class="swot-back">
                                        <ul>
                                            <li>Industry giants' monopoly on eye drops market</li>
                                            <li>High European Union compliance costs</li>
                                            <li>Patient skepticism about live engineering bacteria</li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>

                    <style>
                        .swot-container {
                            width: 95%;
                            margin: 2em auto;
                            padding: 20px;
                        }

                        .swot-grid {
                            display: grid;
                            grid-template-columns: repeat(2, 1fr);
                            gap: 20px;
                            margin: 0 auto;
                        }

                        .swot-item {
                            perspective: 1000px;
                            min-height: 200px;
                        }

                        .swot-card {
                            position: relative;
                            width: 100%;
                            height: 100%;
                            min-height: 200px;
                            transition: transform 0.8s;
                            transform-style: preserve-3d;
                            cursor: pointer;
                        }

                        .swot-item:hover .swot-card {
                            transform: rotateY(180deg);
                        }

                        .swot-front, .swot-back {
                            position: absolute;
                            width: 100%;
                            height: 100%;
                            backface-visibility: hidden;
                            border-radius: 20px;
                            padding: 25px;
                        }

                        .swot-front {
                            background-color: inherit;
                        }

                        .swot-back {
                            transform: rotateY(180deg);
                            background-color: white;
                            box-shadow: 0 4px 8px rgba(0,0,0,0.1);
                            display: flex;
                            align-items: center;
                            justify-content: center;
                        }

                        .swot-back ul {
                            list-style: none;
                            padding: 0;
                            margin: 0;
                        }

                        .swot-back li {
                            margin: 10px 0;
                            padding-left: 20px;
                            position: relative;
                            font-size: 0.9em;
                            line-height: 1.4;
                        }

                        .swot-back li::before {
                            content: 'â¢';
                            position: absolute;
                            left: 0;
                            color: #666;
                        }

                        /* ä¿æåæçæ ·å¼ */
                        .swot-title {
                            margin: 0;
                            padding-left: 20px;
                            font-size: 2em;
                            font-weight: normal;
                            color: #666;
                            font-family: 'Comic Sans MS', cursive;
                        }

                        .swot-letter {
                            position: absolute;
                            font-size: 4em;
                            color: rgba(0, 0, 0, 0.15);
                            font-weight: normal;
                        }

                        /* æ´æ°èæ¯é¢è²åºç¨ä½ç½® */
                        .strengths .swot-card .swot-front { background-color: rgba(176, 224, 230, 0.3); }
                        .weaknesses .swot-card .swot-front { background-color: rgba(255, 218, 185, 0.3); }
                        .opportunities .swot-card .swot-front { background-color: rgba(144, 238, 144, 0.3); }
                        .threats .swot-card .swot-front { background-color: rgba(255, 182, 193, 0.3); }
                        
                        /* èé¢æ ·å¼æ´æ° */
                        .swot-back {
                            transform: rotateY(180deg);
                            background-color: white;
                            box-shadow: 0 4px 8px rgba(0,0,0,0.1);
                        }
                        
                        /* ä¸ºèé¢æ·»å å¯¹åºçæ·¡åèæ¯è² */
                        .strengths .swot-card .swot-back { background-color: rgba(176, 224, 230, 0.1); }
                        .weaknesses .swot-card .swot-back { background-color: rgba(255, 218, 185, 0.1); }
                        .opportunities .swot-card .swot-back { background-color: rgba(144, 238, 144, 0.1); }
                        .threats .swot-card .swot-back { background-color: rgba(255, 182, 193, 0.1); }

                        /* ç§»é¤åæçèæ¯è²å®ä¹ */
                        .strengths, .weaknesses, .opportunities, .threats {
                            background-color: transparent;
                        }
                        
                        /* ç¡®ä¿å¡çå æ»¡å®¹å¨ */
                        .swot-card {
                            position: relative;
                            width: 100%;
                            height: 100%;
                            min-height: 200px;
                            transition: transform 0.8s;
                            transform-style: preserve-3d;
                            cursor: pointer;
                        }

                        .swot-front, .swot-back {
                            position: absolute;
                            width: 100%;
                            height: 100%;
                            backface-visibility: hidden;
                            border-radius: 20px;
                            padding: 25px;
                        }

                        /* ååºå¼è®¾è®¡ */
                        @media (max-width: 1000px) {
                            .swot-grid {
                                grid-template-columns: 1fr;
                            }
                        }
                    </style>

                <section id="cooperative">
                    <h1>Potential partners</h1>
                    <!-- Content sections will go here -->

                    <p>planning to cooperate deeply with a certain enterprise, below are the enterprises that we might look into:</p>

                    <div class="table-container">
                        <table>
                            <caption>Potential Strategic Partners</caption>
                            <thead>
                                <tr>
                                    <th>Type</th>
                                    <th>Company/Organization</th>
                                    <th>Cooperation Direction</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td rowspan="2">Pharmaceutical Companies</td>
                                    <td><a href="https://www.eastchinapharm.com/en" target="_blank">Huadong Medicine</a> (Hangzhou)</td>
                                    <td>Jointly develop ophthalmic drug delivery systems and share clinical trial resources.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://www.venusmedtech.com/" target="_blank">Qiming Medical</a> (Hangzhou Medical Port)</td>
                                    <td>With the help of its medical apparatus industrialization experience, accelerate product landing.</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">Contact Lens Manufacturers</td>
                                    <td><a href="https://www.acuvue.com.cn/" target="_blank">Johnson & Johnson</a></td>
                                    <td>Technology licensing cooperation, integrating its global distribution network.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://www.bausch.com/" target="_blank">Bausch & Lomb</a></td>
                                    <td>Jointly launched the "therapeutic contact lens" brand to seize the high-end market.</td>
                                </tr>
                                <tr>
                                    <td>Research Institutions</td>
                                    <td>
                                        <a href="http://www.cmm.zju.edu.cn/cmmenglish/" target="_blank">Zhejiang University School of Medicine</a> 
                                        and 
                                        <a href="https://en.z2hospital.com/" target="_blank">The Second Affiliated Hospital Zhejiang University</a>
                                        (which is the most prominent among all affiliated hospitals in ophthalmology)
                                    </td>
                                    <td>Obtain clinical data, understand the market, and conduct preclinical research.</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">Investment Institutions</td>
                                    <td><a href="https://www.hillhouseinvestment.com/" target="_blank">Hillhouse Capital</a></td>
                                    <td>Focusing on early-stage investment in medical technology, potential A-round lead investor.</td>
                                </tr>
                                <tr>
                                    <td><a href="https://hic.zju.edu.cn/" target="_blank">ZJU-Hangzhou Global Scientific and Technological Innovation Center</a></td>
                                    <td>Provide funds in the early stages of our project.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>

                </section>

                <section id="investment">
                    <h2>Source of Investment</h2>
                    <p>To ensure that the funding needs of the project are met at different stages of development, we have designed diversified financing paths. In the early stage (seed round), we will seek funding from <strong>Zhejiang University</strong> Alumni Fund (such as Zhejiang University Network New Venture Capital), ZJU-Hangzhou Global Scientific and Technological Innovation Center, and Hangzhou's "Young Eagle Plan", mainly for prototype development and preliminary experiments. In the mid-term stage (Series A), we will seek support from venture capital institutions such as Hillhouse Capital and Sequoia China, as well as strategic investments from pharmaceutical companies such as Huadong Medicine. The funds will be used for clinical trials and production line construction. In the later stage (Series B and IPO), we plan to attract international capital (such as Temasek Holdings) and promote listing on the Science and Technology Innovation Board to support global market expansion and brand internationalization.</p>
                </section>

                <h1>Marketing & implementation</h1>
                <section id="request-analysis">
                    <h2>Analysis of user requests</h2>
                    
                    <h3>Core target group - cataract patients</h3>
                    
                    <div class="content-block">
                        <h4>1. Number of cataract patients</h4>
                        <p>In China, the incidence of cataracts increases significantly with age. According to a study conducted in the suburbs of Shanghai, the incidence of cataracts in the population aged 65 and above was <strong>57.0%</strong>. Another study showed that the incidence of cataracts in the population aged 45 and above in rural western China was <strong>45.15%</strong><sup><a href="#ref1">[1]</a>-<a href="#ref2">[2]</a></sup>.</p>

                        <h4>2. Surgical coverage</h4>
                        <p>In China, the coverage rate of cataract surgery is still low. According to a national study, the proportion of cataract surgery between 2011 and 2015 was only <strong>1.22%</strong>. In the suburbs of Shanghai, the coverage rate of cataract surgery among people aged 65 and above is <strong>10.9%</strong>. In rural areas of the southwest, the cataract surgery coverage rate (CSC) is <strong>53.3%</strong>, but there are still a large number of patients who have not undergone surgery<sup><a href="#ref3">[3]</a> <a href="#ref4">[4]</a></sup>. What's more, there exists an apparent inequality in access, below is the figure that shows the distribution of cataract surgeons per 50,000 population in China in 2014.<sup><a href="#ref10">[10]</a></sup></p>

                        <figure>
                            <img src="../../static/img/hp-entre/map.png" alt="Distribution of cataract surgeons per 50,000 population in China" style="width: 60%;">
                            <figcaption>Distribution of cataract surgeons per 50,000 population across China (2014)</figcaption>
                        </figure>

                        <h4>3. Prevalence of dry eye syndrome among contact lens users</h4>
                        <p>Dry eye syndrome has a high incidence in China. According to a multicenter cross-sectional study, the incidence of dry eye syndrome has significantly increased among contact lens wearers. The study showed that the incidence of dry eye syndrome increased significantly among users who wore contact lenses for more than 3 years<sup><a href="#ref5">[5]</a></sup>.</p>
                        
                        <h3>Urgent needs and existing pain points:</h3>
                        <p>The high cost of cataract surgery and the uneven distribution of medical resources are indeed major issues. The low absorption rate of traditional eye drops (< 5%) and the need for frequent use (6-8 times a day) are also significant pain points.</p>
                    
                    </div>
                </section>

                <section id="marketing-strategy">
                    <h2>Marketing strategy</h2>
                    <!-- Content sections will go here -->
                    <ol>
                        <li><p><strong>Target market segmentation: </strong>We divide the market into <strong>core and secondary groups</strong>. The core group includes cataract patients, with a special focus on developing countries (such as India and Africa) and countries with severe aging (such as China and Japan). Among them, we will use <strong>China</strong> as the starting point of our project's market. In addition, the high-risk group of dry eye syndrome, such as young white-collar workers and contact lens wearers who use electronic devices for a long time, is also our focus. The secondary group covers medical institutions (such as hospitals and clinics) and public welfare organizations (such as the International Association for the Prevention of Blindness) to expand the social impact of the product.</p></li>
                        <li><p><strong>Value proposition: </strong>Our core message focuses on three major highlights: firstly, <strong>"non-surgical treatment"</strong>, with the slogan "Say goodbye to surgical knives, weekly disposable lenses reverse cataracts", emphasizing the innovation of the product; secondly, <strong>"long-lasting convenience"</strong>, conveying the convenience of product use through "one-time wear, continuous treatment"; finally, <strong>"combination therapy"</strong>, highlighting the multiple effects of "one lens, simultaneously solving cataracts and dry eye syndrome", meeting the comprehensive needs of different patients.</p></li>
                        <li><p><strong>Channel strategy: </strong><strong>In the B2B field</strong>, we will cooperate with top Hospitals to strive to include our products in the medical insurance catalog and quickly enter the medical market through existing channels of partners such as Huadong Medicine and Qiming Medical. <strong>In the B2C field</strong>, we plan to open flagship stores on e-commerce platforms such as Tmall and JD.com Health, providing subscription services for monthly delivery. At the same time, we will set up product experience counters in offline chain pharmacies to enhance consumers' experience.</p></li>
                        <li><p><strong>Promotion strategy: </strong>In terms of promotion, we will combine three strategies: <strong>authoritative endorsement, digital marketing, and public welfare linkage</strong>. Firstly, we plan to invite <strong>Professor Yao Ke</strong> from the School of Medicine of Zhejiang University to release clinical trial data, enhance the credibility of the technology, and jointly release the "White Paper on Non-Surgical Treatment of Cataracts" with the medical department of Zhejiang University  to enhance international influence. Secondly, we will carry out digital marketing, launch a popular science short video "3 Minutes to Understand Your Eyes" through <strong>digital platforms</strong> like Douyin, strive to break through 100,000 + views and share real wearing experiences with <strong>KOL on REDNOTES</strong> to create hot topics such as #Contact Lenses for Cataract #. Finally, we will implement the "Buy One Donate One" public welfare plan, donating a public welfare version of the product to patients in Africa or  remote rural areas in China for every lens sold, balancing commercial value and social responsibility.</p></li>
                        <li><p><strong>Pricing strategy: </strong>In terms of pricing, we will adopt a differentiated strategy. For the <strong>high-end market</strong>, weekly disposable lenses are priced at 300 or more yuan per lens, referring to Johnson & Johnson's pricing system (attachment 1), while considering the therapeutic value and production cost of the product.</p></li>
                    </ol>
                    <div class="quote">
                        Johnson & Johnson's pricing system: Hydrogel material Johnson & Johnson Moisturizing biweekly contact lenses 6 pieces pack about 75; Silicone hydrogel material Johnson & Johnson Comfort biweekly contact lenses 6 pieces pack about 199
                    </div>
                    <p><strong>In developing countries</strong>, we will provide public welfare products that are sold at cost or partially covered by government subsidies and donations to reduce the burden on patients. In addition, we will launch a subscription discount policy, where customers can enjoy a 10% discount for 6 consecutive months, thus binding long-term users.</p>
                </section>

                <section id="implementation">
                    <h2>Implementation strategy</h2>
                    
                    <h3 class="gradient-underline">1. Phased Implementation</h3>
                    <div class="timeline">
                        <div class="timeline-item">
                            <div class="timeline-date">2026-2027</div>
                            <div class="timeline-content">
                                <h4>Pilot Phase</h4>
                                <ul>
                                    <li>Conduct clinical trials in 3 tier-1 hospitals in Hangzhou</li>
                                    <li>Cover 500 patients and accumulate initial data</li>
                                    <li>Open online pre-sale channel with Ali Health</li>
                                    <li>Collect first batch of user feedback</li>
                                </ul>
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2027-2029</div>
                            <div class="timeline-content">
                                <h4>Expansion Phase</h4>
                                <ul>
                                    <li>Establish GMP factory in Hangzhou Pharmaceutical Port</li>
                                    <li>Achieve annual production capacity of 10 million units</li>
                                    <li>Expand to markets like India and Kenya</li>
                                    <li>Collaborate with local medical institutions</li>
                                </ul>
                            </div>
                        </div>
                        <div class="timeline-item">
                            <div class="timeline-date">2029-2030</div>
                            <div class="timeline-content">
                                <h4>Globalization Stage</h4>
                                <ul>
                                    <li>Complete FDA and CE certification</li>
                                    <li>Enter European and American markets</li>
                                    <li>Develop extended product lines (glaucoma, retinopathy)</li>
                                    <li>Expand business territory globally</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <h3 class="gradient-underline">2. Partner Ecosystem</h3>
                    <div class="ecosystem-container">
                        <div class="ecosystem-item">
                            <h4>Research & Development</h4>
                            <p>Establish "Ophthalmic Slow-Release Technology Joint Laboratory" with Zhejiang University School of Medicine to promote technological innovation and collaborate with existing labs specializing in hydrogels and cataracts.</p>
                        </div>
                        <div class="ecosystem-item">
                            <h4>Production</h4>
                            <p>Leverage Hangzhou Medical Port Town's resources to create a green production system and optimize supply chain management.</p>
                        </div>
                        <div class="ecosystem-item">
                            <h4>Public Welfare</h4>
                            <p>Partner with International Association for the Prevention of Blindness (IAPB), participate in global anti-blindness programs, and expand brand social influence.</p>
                        </div>
                    </div>

                    <h3 class="gradient-underline">3. User Support System</h3>
                    <div class="support-container">
                        <div class="support-item">
                            <h4>Digital Support</h4>
                            <ul>
                                <li>"ClearLens Assistant" Mini Program with video tutorials</li>
                                <li>Online consultation service</li>
                                <li>24/7 customer service hotline (400)</li>
                            </ul>
                        </div>
                        <div class="support-item">
                            <h4>After-sales Service</h4>
                            <ul>
                                <li>Follow-up questionnaires (Day 7 & 30)</li>
                                <li>Continuous product optimization</li>
                                <li>"Worry-free return and exchange" policy with 30-day refund protection</li>
                            </ul>
                        </div>
                    </div>

                    <h3>4. Innovative Thinking</h3>
                    <p>Considering the long and complex approval cycle of medical apparatus, we realize that clinical application still needs time. Therefore, we have decided to shift part of our focus to the potential of scientific research and explore the promotion value of non-clinical products.</p>
                    <p><strong>Microengineered Biomimetic Ocular Models</strong> is the first of its kind, as we did not find any other in vitro devices for anterior whole-layer simulation of the lens.</p>
                    <p>What's more,  we have also designed and constructed a device that integrates <strong>fluorescence signal detection technology</strong> with <strong>a black contact lens container</strong>. By pressing a button, the light source will stimulate the fluorescent protein Crimson, and the fluorescence intensity will be monitored by the BH1750 sensor. </p>
                    <p>It not only has <strong>innovative technical characteristics</strong>, but also can provide <strong>support for future medical development</strong> as a scientific research tool.</p>
                    <p>Our project has demonstrated its huge potential in technological innovation and scientific research. We believe that over time, these innovations will gradually be integrated into practical applications and bring positive social impacts. In this way, we not only contribute technically, but also take firm steps in promoting sustainable development in the medical field.</p>
                </section>

                <style>
                    /* Timeline styles */
                    .timeline {
                        position: relative;
                        padding: 20px 0;
                        margin: 20px 0;
                    }

                    .timeline::before {
                        content: '';
                        position: absolute;
                        left: 50px;
                        top: 0;
                        bottom: 0;
                        width: 4px;
                        background: linear-gradient(180deg, #3498db 0%, #2ecc71 100%);
                        border-radius: 5px;
                    }

                    .timeline-item {
                        padding: 35px 35px 35px 100px;
                        margin: 40px 0;
                        background: linear-gradient(120deg, rgba(255, 255, 255, 0.9), rgba(255, 255, 255, 0.95));
                        border-radius: 20px;
                        position: relative;
                        box-shadow: 0 10px 30px rgba(0, 0, 0, 0.05);
                        transition: all 0.4s cubic-bezier(0.215, 0.61, 0.355, 1);
                        backdrop-filter: blur(10px);
                        border: 1px solid rgba(255, 255, 255, 0.5);
                    }

                    .timeline-item:hover {
                        transform: translateY(-5px) translateX(5px);
                        box-shadow: 0 20px 40px rgba(0, 0, 0, 0.08);
                        background: linear-gradient(120deg, rgba(255, 255, 255, 0.95), rgba(255, 255, 255, 1));
                    }

                    .timeline-item::before {
                        content: '';
                        position: absolute;
                        left: 42px;
                        top: 40px;
                        width: 24px;
                        height: 24px;
                        border-radius: 50%;
                        background: #fff;
                        border: 4px solid #3498db;
                        box-shadow: 0 0 0 6px rgba(52, 152, 219, 0.2);
                        z-index: 1;
                        transition: all 0.3s ease;
                    }

                    .timeline-item:hover::before {
                        transform: scale(1.2);
                        box-shadow: 0 0 0 8px rgba(52, 152, 219, 0.3);
                    }

                    .timeline-date {
                        font-weight: 600;
                        color: #3498db;
                        margin-bottom: 15px;
                        font-size: 1.2em;
                        letter-spacing: 0.5px;
                        opacity: 0.9;
                        transition: all 0.3s ease;
                    }

                    .timeline-item:hover .timeline-date {
                        opacity: 1;
                        transform: translateX(5px);
                    }

                    .timeline-content h4 {
                        color: #2c3e50;
                        margin-bottom: 20px;
                        font-size: 1.5em;
                        font-weight: 600;
                        transition: all 0.3s ease;
                    }

                    .timeline-item:hover .timeline-content h4 {
                        transform: translateX(5px);
                    }

                    .timeline-content ul {
                        padding-left: 0;
                        list-style: none;
                    }

                    .timeline-content li {
                        margin: 15px 0;
                        color: #34495e;
                        line-height: 1.6;
                        padding-left: 30px;
                        position: relative;
                        transition: all 0.3s ease;
                    }

                    .timeline-content li::before {
                        content: 'ð¾';  /* ä½¿ç¨çªå°emojiä½ä¸ºåè¡¨æ è®° */
                        position: absolute;
                        left: 0;
                        color: #3498db;
                        opacity: 0.7;
                        transform: scale(0.9);
                        transition: all 0.3s ease;
                    }

                    .timeline-item:hover .timeline-content li {
                        transform: translateX(5px);
                    }

                    .timeline-item:hover .timeline-content li::before {
                        opacity: 1;
                        transform: scale(1);
                    }

                    /* ä¸ºæ¯ä¸ªæ¶é´çº¿é¡¹ç®æ·»å ä¸åçå¾®å¦èæ¯è² */
                    .timeline-item:nth-child(1) {
                        background: linear-gradient(120deg, rgba(240, 248, 255, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .timeline-item:nth-child(2) {
                        background: linear-gradient(120deg, rgba(240, 255, 244, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .timeline-item:nth-child(3) {
                        background: linear-gradient(120deg, rgba(255, 248, 240, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    /* æ·»å è¿å¥å¨ç» */
                    @keyframes slideInFromLeft {
                        from {
                            opacity: 0;
                            transform: translateX(-50px);
                        }
                        to {
                            opacity: 1;
                            transform: translateX(0);
                        }
                    }

                    .timeline-item {
                        animation: slideInFromLeft 0.6s ease-out forwards;
                        opacity: 0;
                    }

                    .timeline-item:nth-child(1) { animation-delay: 0.2s; }
                    .timeline-item:nth-child(2) { animation-delay: 0.4s; }
                    .timeline-item:nth-child(3) { animation-delay: 0.6s; }

                    /* Ecosystem styles */
                    .ecosystem-container {
                        display: grid;
                        grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
                        gap: 25px;
                        margin: 30px 0;
                    }

                    .ecosystem-item {
                        padding: 35px;
                        background: linear-gradient(120deg, rgba(255, 255, 255, 0.9), rgba(255, 255, 255, 0.95));
                        border-radius: 20px;
                        position: relative;
                        box-shadow: 0 10px 30px rgba(0, 0, 0, 0.05);
                        transition: all 0.4s cubic-bezier(0.215, 0.61, 0.355, 1);
                        backdrop-filter: blur(10px);
                        border: 1px solid rgba(255, 255, 255, 0.5);
                        overflow: hidden;
                    }

                    .ecosystem-item:hover {
                        transform: translateY(-5px);
                        box-shadow: 0 20px 40px rgba(0, 0, 0, 0.08);
                    }

                    /* ä¸ºæ¯ä¸ªå¡çæ·»å ä¸åçèæ¯è² */
                    .ecosystem-item:nth-child(1) {
                        background: linear-gradient(120deg, rgba(240, 248, 255, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .ecosystem-item:nth-child(2) {
                        background: linear-gradient(120deg, rgba(240, 255, 244, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .ecosystem-item:nth-child(3) {
                        background: linear-gradient(120deg, rgba(255, 248, 240, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .ecosystem-item h4 {
                        color: #2c3e50;
                        font-size: 1.4em;
                        margin-bottom: 20px;
                        position: relative;
                        padding-bottom: 15px;
                    }

                    .ecosystem-item h4::after {
                        content: '';
                        position: absolute;
                        left: 0;
                        bottom: 0;
                        width: 40px;
                        height: 3px;
                        background: linear-gradient(90deg, #3498db, #2ecc71);
                        border-radius: 3px;
                        transition: width 0.3s ease;
                    }

                    .ecosystem-item:hover h4::after {
                        width: 60px;
                    }

                    .ecosystem-item p {
                        color: #34495e;
                        line-height: 1.7;
                        transition: all 0.3s ease;
                    }

                    .ecosystem-item:hover p {
                        transform: translateX(5px);
                    }

                    /* æ·»å è£é¥°æ§åç´  */
                    .ecosystem-item::before {
                        content: '';
                        position: absolute;
                        top: 0;
                        right: 0;
                        width: 100px;
                        height: 100px;
                        background: linear-gradient(135deg, transparent 50%, rgba(52, 152, 219, 0.1) 50%);
                        border-top-right-radius: 20px;
                    }

                    /* æ·»å è¿å¥å¨ç» */
                    @keyframes fadeInUp {
                        from {
                            opacity: 0;
                            transform: translateY(30px);
                        }
                        to {
                            opacity: 1;
                            transform: translateY(0);
                        }
                    }

                    .ecosystem-item {
                        animation: fadeInUp 0.6s ease-out forwards;
                        opacity: 0;
                    }

                    .ecosystem-item:nth-child(1) { animation-delay: 0.2s; }
                    .ecosystem-item:nth-child(2) { animation-delay: 0.4s; }
                    .ecosystem-item:nth-child(3) { animation-delay: 0.6s; }

                    /* ååºå¼è°æ´ */
                    @media (max-width: 768px) {
                        .ecosystem-container {
                            grid-template-columns: 1fr;
                        }
                        
                        .ecosystem-item {
                            padding: 25px;
                        }
                    }

                    /* Support system styles */
                    .support-container {
                        display: grid;
                        grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
                        gap: 25px;
                        margin: 30px 0;
                    }

                    .support-item {
                        padding: 30px;
                        background: linear-gradient(120deg, rgba(255, 255, 255, 0.9), rgba(255, 255, 255, 0.95));
                        border-radius: 15px;
                        box-shadow: 0 10px 30px rgba(0, 0, 0, 0.05);
                        transition: all 0.3s ease;
                        backdrop-filter: blur(10px);
                        border: 1px solid rgba(255, 255, 255, 0.5);
                    }

                    .support-item:hover {
                        transform: translateY(-5px);
                        box-shadow: 0 15px 35px rgba(0, 0, 0, 0.1);
                    }

                    .support-item h4 {
                        color: #2c3e50;
                        font-size: 1.4em;
                        margin-bottom: 20px;
                        padding-bottom: 10px;
                        border-bottom: 2px solid rgba(52, 152, 219, 0.2);
                        position: relative;
                    }

                    .support-item h4::after {
                        content: '';
                        position: absolute;
                        left: 0;
                        bottom: -2px;
                        width: 50px;
                        height: 2px;
                        background: linear-gradient(90deg, #3498db, #2ecc71);
                        transition: width 0.3s ease;
                    }

                    .support-item:hover h4::after {
                        width: 100%;
                    }

                    .support-item ul {
                        list-style: none;
                        padding: 0;
                        margin: 0;
                    }

                    .support-item li {
                        margin: 15px 0;
                        padding-left: 35px;
                        position: relative;
                        color: #34495e;
                        line-height: 1.6;
                        transition: all 0.3s ease;
                    }

                    .support-item li::before {
                        content: 'ð¾';
                        position: absolute;
                        left: 0;
                        top: 50%;
                        transform: translateY(-50%) scale(0.9);
                        color: #3498db;
                        opacity: 0.7;
                        transition: all 0.3s ease;
                    }

                    .support-item:hover li {
                        transform: translateX(5px);
                    }

                    .support-item:hover li::before {
                        opacity: 1;
                        transform: translateY(-50%) scale(1.1);
                    }

                    /* ä¸ºä¸åé¨åæ·»å ä¸åçèæ¯è² */
                    .support-item:nth-child(1) {
                        background: linear-gradient(120deg, rgba(240, 248, 255, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    .support-item:nth-child(2) {
                        background: linear-gradient(120deg, rgba(240, 255, 244, 0.95), rgba(255, 255, 255, 0.95));
                    }

                    /* æ·»å è¿å¥å¨ç» */
                    @keyframes slideInFromRight {
                        from {
                            opacity: 0;
                            transform: translateX(50px);
                        }
                        to {
                            opacity: 1;
                            transform: translateX(0);
                        }
                    }

                    .support-item {
                        animation: slideInFromRight 0.6s ease-out forwards;
                        opacity: 0;
                    }

                    .support-item:nth-child(1) { animation-delay: 0.2s; }
                    .support-item:nth-child(2) { animation-delay: 0.4s; }

                    /* ååºå¼è°æ´ */
                    @media (max-width: 768px) {
                        .support-container {
                            grid-template-columns: 1fr;
                        }
                        
                        .support-item {
                            padding: 20px;
                        }
                    }

                    /* Innovation section styles */
                    .innovation-section {
                        padding: 30px;
                        background: linear-gradient(120deg, rgba(240, 248, 255, 0.95), rgba(255, 255, 255, 0.95));
                        border-radius: 20px;
                        box-shadow: 0 10px 30px rgba(0, 0, 0, 0.05);
                        position: relative;
                        overflow: hidden;
                        backdrop-filter: blur(10px);
                        border: 1px solid rgba(255, 255, 255, 0.5);
                        margin: 30px 0;
                    }

                    .innovation-intro {
                        font-size: 1.2em;
                        color: #34495e;
                        line-height: 1.6;
                        margin-bottom: 30px;
                        padding-left: 20px;
                        border-left: 4px solid #3498db;
                        background: rgba(255, 255, 255, 0.5);
                        padding: 15px 20px;
                        border-radius: 0 10px 10px 0;
                        transition: all 0.3s ease;
                    }

                    .innovation-intro:hover {
                        transform: translateX(5px);
                        background: rgba(255, 255, 255, 0.8);
                    }

                    .device-section {
                        background: rgba(255, 255, 255, 0.7);
                        padding: 25px;
                        border-radius: 15px;
                        margin: 20px 0;
                        transition: all 0.3s ease;
                    }

                    .device-section:hover {
                        transform: translateY(-5px);
                        box-shadow: 0 15px 30px rgba(0, 0, 0, 0.1);
                    }

                    .device-title {
                        color: #2c3e50;
                        font-size: 1.4em;
                        margin-bottom: 20px;
                        padding-bottom: 10px;
                        border-bottom: 2px solid rgba(52, 152, 219, 0.2);
                        position: relative;
                    }

                    .device-title::after {
                        content: '';
                        position: absolute;
                        left: 0;
                        bottom: -2px;
                        width: 50px;
                        height: 2px;
                        background: linear-gradient(90deg, #3498db, #2ecc71);
                        transition: width 0.3s ease;
                    }

                    .device-section:hover .device-title::after {
                        width: 100%;
                    }

                    .feature-list {
                        list-style: none;
                        padding: 0;
                        margin: 0;
                    }

                    .feature-list li {
                        margin: 15px 0;
                        padding-left: 35px;
                        position: relative;
                        color: #34495e;
                        line-height: 1.6;
                        transition: all 0.3s ease;
                    }

                    .feature-list li::before {
                        content: 'ð¬';  /* ä½¿ç¨æ¾å¾®éemojiä½ä¸ºç§æç¸å³çæ è®° */
                        position: absolute;
                        left: 0;
                        top: 50%;
                        transform: translateY(-50%) scale(0.9);
                        opacity: 0.7;
                        transition: all 0.3s ease;
                    }

                    .device-section:hover .feature-list li {
                        transform: translateX(5px);
                    }

                    .device-section:hover .feature-list li::before {
                        opacity: 1;
                        transform: translateY(-50%) scale(1.1);
                    }

                    .conclusion {
                        margin-top: 30px;
                        padding: 20px;
                        background: rgba(52, 152, 219, 0.1);
                        border-radius: 10px;
                        color: #34495e;
                        line-height: 1.7;
                        position: relative;
                        transition: all 0.3s ease;
                    }

                    .conclusion:hover {
                        background: rgba(52, 152, 219, 0.15);
                        transform: translateY(-3px);
                    }

                    /* æ·»å è¿å¥å¨ç» */
                    @keyframes fadeInScale {
                        from {
                            opacity: 0;
                            transform: scale(0.95);
                        }
                        to {
                            opacity: 1;
                            transform: scale(1);
                        }
                    }

                    .innovation-section {
                        animation: fadeInScale 0.6s ease-out forwards;
                    }

                    /* ååºå¼è°æ´ */
                    @media (max-width: 768px) {
                        .innovation-section {
                            padding: 20px;
                        }
                        
                        .device-section {
                            padding: 20px;
                        }
                    }
                </style>

                <h1>Risk Analysis</h1>
                <div class="quote">
                    "Risk is not the end, but the starting point of iteration" - with a systematic plan to transform the crisis into differentiated competitiveness.  
                </div>
                <section id="Deterministic">
                    <h2>Deterministic Analysis</h2>
                    <p>Deterministic risk refers to risks that are clearly present and can be partially or fully controlled by existing strategies.</p>

                    <ol>
                        <li><p><strong>Biosecurity and compliance risks: </strong>Engineering bacteria leakage may cause ecological or health problems. Although the risk has been greatly reduced through hydrogel packaging and biosafety reporting to the pathway design, strict monitoring of the production environment is still required during the mass production stage. In addition, the approval cycle for the third type of medical apparatus is long (3-5 years), and it needs to rely on the "green channel" policy of the Hangzhou Medical Products Administration to accelerate the process. If the policy support is insufficient or the regulations change, the product may be delayed.</p></li>
                        <li><p><strong>Production costs and scaling challenges: </strong>The production cost of bio-hydrogels and engineering bacteria is relatively high, especially in the initial stage of scale. For example, non-petroleum-based alternative materials for polyvinyl alcohol (PVA) are not yet fully mature, and dependence on imports may lead to supply chain fluctuations. By cooperating with Huadong Medicine to optimize the production process and taking advantage of tax incentives at Hangzhou Medical Port, some cost pressures can be hedged, but the profit margin may still be lower than expected in the short term.</p></li>
                        <li><p><strong>Market competition squeeze: </strong>Traditional surgery and nano eye drops are still the mainstream solutions. If giants like Novartis launch similar sustained-release technology products in advance, it may dilute the market uniqueness of ClearLens Â®. By rapidly advancing patent layouts (such as RNF114 targeted modification technology) and binding hospital channels, a first-mover advantage can be built, but continuous investment in research and development is still needed to maintain technological leadership.</p></li>
                    </ol>
                </section>

                <section id="Uncertainty">
                    <h2>Uncertainty risk</h2>
                    <p>Uncertainty risk refers to external factors that are difficult to quantify or predict and require dynamic adjustment.</p>
                    <ol>
                        <li><p><strong>Patient Acceptance and Educational Barriers: </strong>Although the project conducts market education through public welfare screening and endorsement by KOL doctors, some patients still have doubts about "live engineering bacteria", especially in areas with low cultural levels or conservatism. If the initial clinical trial data (such as 5% stimulating feedback) is amplified and disseminated, it may affect brand trust. A real-time Public Opinion Monitoring system needs to be established, and concerns should be alleviated through transparent disclosure of safety data (such as third-party biosafety reports).</p></li>
                        <li><p><strong>Technology substitution and disruptive innovation: </strong>Gene therapy or stem cell regeneration technology may directly overturn existing treatment plans if breakthroughs are made in the next 5 years. Projects need to maintain technological scalability, such as reserving interfaces to support future integration of gene therapy modules or supplementing technical gaps through mergers and acquisitions of start-ups.</p></li>  
                        <li><p><strong>International policies and supply chain fluctuations: </strong>The certification requirements for degradable materials under the European Union REACH regulation may be upgraded, leading to increased export costs. Geopolitical conflicts may also affect the global supply chain of SHuffle's engineering bacteria chassis. Therefore, it is necessary to establish redundant production lines at Hangzhou Medical Port and reserve key raw materials for 3-6 months in advance.</p></li>
                    </ol>
                </section>

                <section id="references">
                    <h1>Reference</h1>
                    <div class="reference-list">
                        <div class="reference-item" id="ref1">
                            <span class="ref-number">[1]</span>
                            <span class="ref-content">Zhang S, Chen J, Yang F, et al. Prevalence rates of cataract and cataract surgery in elderly Chinese people living in suburban Shanghai: the Pujiang Cataract Cohort Study. <em>Br J Ophthalmol</em>. 2023;107(5):683-689.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/35086805/" class="ref-link" target="_blank">DOI: 10.1136/bjophthalmol-2021-319991</a>
                        </div>
                
                        <div class="reference-item" id="ref2">
                            <span class="ref-number">[2]</span>
                            <span class="ref-content">Du K, Guan H, Zhang Y, et al. Knowledge of cataracts and eye care utilization among adults aged 50 and above in rural Western China. <em>Front Public Health</em>. 2022;10:1034314.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36457322/" class="ref-link" target="_blank">DOI: 10.3389/fpubh.2022.1034314</a>
                        </div>
                
                        <div class="reference-item" id="ref3">
                            <span class="ref-number">[3]</span>
                            <span class="ref-content">Jan C, Xin J, Dong Y, et al. Patterns and determinants of incident cataract surgery in China from 2011 to 2015 using a nationally representative longitudinal database. <em>BMJ Open</em>. 2023;13(6):e069702.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/37344116/" class="ref-link" target="_blank">DOI: 10.1136/bmjopen-2022-069702</a>
                        </div>
                
                        <div class="reference-item" id="ref4">
                            <span class="ref-number">[4]</span>
                            <span class="ref-content">Shen W, Cun Q, Zhong H, et al. Ethnic variation in prevalence, self-reported barriers and outcome of cataract surgery in a rural population in southwestern China. <em>BMC Public Health</em>. 2020;20(1):893.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/32517668/" class="ref-link" target="_blank">DOI: 10.1186/s12889-020-09009-5</a>
                        </div>
                
                        <div class="reference-item" id="ref5">
                            <span class="ref-number">[5]</span>
                            <span class="ref-content">Yang W, Wang H, Li J, et al. Demographic and lifestyle factors associated with dry eye disease in China: A cross-sectional multi-center study. <em>Ocul Surf</em>. 2024;34:146-155.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/39074684/" class="ref-link" target="_blank">DOI: 10.1016/j.jtos.2024.07.007</a>
                        </div>
                
                        <div class="reference-item" id="ref6">
                            <span class="ref-number">[6]</span>
                            <span class="ref-content">Hashemi H, Fayaz F, Hashemi A, et al. Global prevalence of cataract surgery. <em>Curr Opin Ophthalmol</em>. 2025;36(1):10-17.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/39638415/" class="ref-link" target="_blank">DOI: 10.1097/ICU.0000000000001092</a>
                        </div>
                
                        <div class="reference-item" id="ref7">
                            <span class="ref-number">[7]</span>
                            <span class="ref-content">Yang Y, Lockwood A. Topical ocular drug delivery systems: Innovations for an unmet need. <em>Exp Eye Res</em>. 2022;218:109006.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/35248559/" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2022.109006</a>
                        </div>
                
                        <div class="reference-item" id="ref8">
                            <span class="ref-number">[8]</span>
                            <span class="ref-content">Hu J, Ma Q, Xin C, Jiao Y. Analysis of Drug Clinical Trials for Eye Diseases in China. <em>J Ocul Pharmacol Ther</em>. 2022;38(9):645-653.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36264174/" class="ref-link" target="_blank">DOI: 10.1089/jop.2021.0126</a>
                        </div>
                
                        <div class="reference-item" id="ref9">
                            <span class="ref-number">[9]</span>
                            <span class="ref-content">Chauhan A, Fitzhenry L, Serro AP. Recent Advances in Ophthalmic Drug Delivery. <em>Pharmaceutics</em>. 2022;14(10):2075.</span>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/36297511/" class="ref-link" target="_blank">DOI: 10.3390/pharmaceutics14102075</a>
                        </div>
                
                        <div class="reference-item" id="ref10">
                            <span class="ref-number">[10]</span>
                            <span class="ref-content">An L, Jan CL, Feng J, et al. Inequity in Access: Cataract Surgery Throughput of Chinese Ophthalmologists from the China National Eye Care Capacity and Resource Survey. <em>Ophthalmic Epidemiology</em>. 2019;27(1):29-38.</span>
                            <a href="https://doi.org/10.1080/09286586.2019.1678654" class="ref-link" target="_blank">DOI: 10.1080/09286586.2019.1678654</a>
                        </div>
                    </div>
                </section>
            
            </div>
        </div>

        <!-- Footer -->
        <footer id="footer">
            <div class="logo_wrap">
                <img id="team_logo" src="../../static/img/Logo-round-text.svg" alt="">
            </div>
            <div class="follow">
                <div class="title">Follow Us</div>
                <ul class="follow_list">
                    <li><a href="https://space.bilibili.com/700401359?spm_id_from=333.337.search-card.all.click" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-bilibili.png" alt=""></a></li>
                    <li><a href="https://twitter.com/ZjuChina" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-twitter.png" alt=""></a></li>
                    <li><a href="https://mp.weixin.qq.com/s/yTMIiH4AQ2skqP-7cXr7Ig" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-wechat.png" alt=""></a></li>
                </ul>
            </div>
            <div class="contact">
                <div class="title">Contact Us</div>
                <div class="email">ZJU_China@outlook.com</div>
            </div>
        </footer>

        <script src="../../static/js/basic.js"></script>
        <script src="../../static/js/pages.js"></script>
        <script src="../../static/js/pdbviewer.js"></script>
        <script src="../../static/js/components.js"></script>
    </body>
</html>